

MODULATION OF SC FUNCTION TO TREAT GLAUCOMA

Tech ID: 30102 / UC Case 2019-089-0

PATENT STATUS

Country	Type	Number	Dated	Case
Japan	Issued Patent	7641902	02/27/2025	2019-089
United States Of America	Published Application	20210363247	11/25/2021	2019-089

Additional Patents Pending

BRIEF DESCRIPTION

Glaucoma is a leading blinding disease affecting at least 60 million people worldwide. A major risk factor for glaucoma is high intraocular pressure (IOP), which can damage the optic nerve and cause permanent blindness without treatment. UC researchers have found that Schlemm's canal (SC) is a critical structure involved in aqueous humor drainage and IOP regulation and have found certain receptors that are expressed on SC. The researchers are working to develop several molecules that can be targeted or modulated to regulate SC function to treat glaucoma.

SUGGESTED USES

» treatment of glaucoma or to lower IOP

ADVANTAGES

» provide new and alternative targets to treat glaucoma, as existing treatments are of limited efficacy with many side effects, and surgeries often fail with scar formation and fibrosis

ADDITIONAL TECHNOLOGIES BY THESE INVENTORS

- [Modulation Of Wnt5a To Treat Glaucoma](#)
- [Live Imaging of Corneal Lymphatic Vessels](#)

CONTACT

Laleh Shayesteh
lalehs@berkeley.edu
tel: 510-642-4537.



INVENTORS

» Chen, Lu

OTHER INFORMATION

CATEGORIZED AS

- » **Optics and Photonics**
- » All Optics and Photonics
- » **Imaging**
- » Medical
- » **Medical**
- » Therapeutics

RELATED CASES

2019-089-0

